Merck & Co., Inc. — 13F Holdings & Portfolio
CIK 310158 · latest 13F-HR filed 2026-08-07
Merck & Co., Inc. manages $526.4M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PSNL (35.75%), MRNA (30.71%), KYMR (16.82%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions, exited 4, added to 8, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
P.O. BOX 2000
RAHWAY, NJ 07065
$526.4M
Long-equity book
13
Distinct positions
2026-06-30
Filed 2026-08-07
+3 / −4 / ↑8 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- PERSONALIS INC$98.7M +110.4%
- MODERNA INC$44.4M +37.9%
- KYMERA THERAPEUTICS INC$24.2M +37.7%
- AKTIS ONCOLOGY INC$13.7M +80.2%
- EIKON THERAPEUTICS INC$4.1M +23.3%
New Positions
- ENTRADA THERAPEUTICS INC$12.8M
- SUTRO BIOPHARMA INC$9.0M
- EVAXION BIOTECH A/S$3.8M
Exited Positions
- ENTRADA THERAPEUTICS INC$22.0M
- SUTRO BIOPHARMA INC$6.8M
- EVAXION BIOTECH A/S$4.5M
- CARISMA THERAPEUTICS INC$47.9K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PERSONALIS INC | PSNL | 71535D106 | $188.2M | 35.75% | 14,044,943 | SH |
| 2 | MODERNA INC | MRNA | 60770K107 | $161.6M | 30.71% | 2,308,190 | SH |
| 3 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $88.5M | 16.82% | 772,165 | SH |
| 4 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $30.7M | 5.83% | 952,844 | SH |
| 5 | EIKON THERAPEUTICS INC | EIKN | 282564103 | $21.7M | 4.13% | 1,666,666 | SH |
| 6 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $12.8M | 2.43% | 1,739,768 | SH |
| 7 | SUTRO BIOPHARMA INC | STRO | 869367201 | $9.0M | 1.72% | 272,351 | SH |
| 8 | ALECTOR INC | ALEC | 014442107 | $7.1M | 1.35% | 3,545,719 | SH |
| 9 | EVAXION BIOTECH A/S | EVAX | 29970R303 | $3.8M | 0.71% | 1,214,126 | SH |
| 10 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $1.7M | 0.33% | 93,414 | SH |
| 11 | XILIO THERAPEUTICS INC | XLO | 98422T209 | $1.0M | 0.19% | 105,982 | SH |
| 12 | TUHURA BIOSCIENCES INC | HURA | 898920103 | $45.5K | 0.01% | 19,445 | SH |
| 13 | NEUPHORIA THERAPEUTICS INC | NEUP | 64136E102 | $43.8K | 0.01% | 10,027 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-07 | $526.4M | 13 | 0000310158-26-000210 |
| 2026-03-31 | 2026-05-13 | $349.4M | 14 | 0000310158-26-000141 |
| 2025-12-31 | 2026-02-17 | $276.3M | 12 | 0000310158-26-000055 |
| 2025-09-30 | 2025-11-12 | $228.0M | 13 | 0000310158-25-000063 |